Figure 2From: Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Incremental costs (or cost savings) associated with use of RDTs when malaria is confirmed in varying proportions of patients for two ACTs (artesunate plus sulfadoxine-pyrimethamine and artemether-lumefantrine); excluding 'other recurrent costs'. Back to article page